Phase II study to test in first line the VAD (Vincristine Adriablastine Dexamethasone) + C (Chlorambucil ) regimen associated to rituximab ( R-VAD + C ) in a cohort of young patients under 66 years with a mantle cell lymphoma and also the test the role of an in vivo marrow purge with rituximab before an autologous stem cell transplantation for the consolidation of the patients which fulfilled a response to 4 cycles of (R VAD + C) regimen.

All patients at diagnosis with a stage II, III or IV an arbor disease are treated with 4 cycles of (R VAD +C) .

The responders more than RP > 50% received 2 other cycles before to be intensified with alkeran 140 mg/ m2 and a 8 grays TBI over 4 days before an autologous PBSCT.The stem cell collection is realised after a mobilisation with HD Cyclophosphamide (4 mg/m2) after the four R-(VAD + C) cycles and purged by a rituximab injection 10 days before the collection.

There is an clinical and molecular evaluation of the strategy

Inclusion Criteria:

• Mantel cell lymphoma
• CD 20+
• At diagnosis or without anterior chemotherapy
• Age >18 and < 66 years
• Ann Arbor ii, III or IV
• ECOG <3
• contraindication for rituximab treatment
• Informed consent signed
• No cancer anteriory
• Renal and hepatic function compatible with the treatment
• Ventricular Fraction > 50 % with echographic method and > 40% with isotopic method

Exclusion Criteria:

• Other type of lymphoma
• age<18 ou > 66 years
• Informed consent not signed
• anterior cancer
• Contraindication to rituximab
• Cardiac insufficiency